Modified bispecific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 show higher ADCC potential and in vivo anti-tumor response

Authors

Ashley Gelin, The University of Texas MD Anderson Cancer CenterFollow
Coline Agnes Couillault, The University of Texas MD Anderson Cancer Center
Anupallavi Srinivasamani, The University of Texas MD Anderson Cancer Center
Qinying Liu, The University of Texas MD Anderson Cancer Center
Michael Andrew Curran, The University of Texas MD Anderson Cancer Center

Files

Publisher

The University of Texas MD Anderson Cancer Center

City

Houston

Keywords

Bispecific antibodies, monospecific antibodies, ADCC, programmed death ligand 1

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.

Program Affiliation

CPRIT-CURE Summer Undergraduate Program

Recommended Citation

Gelin, Ashley; Couillault, Coline Agnes; Srinivasamani, Anupallavi; Liu, Qinying; and Curran, Michael Andrew, "Modified bispecific antibodies blocking both PD-L1 and PD-L2 engagement of PD-1 show higher ADCC potential and in vivo anti-tumor response" (2021). Summer Experience 2021. 55.
https://openworks.mdanderson.org/sumexp21/55